Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumor, KRAS Mutation”

143 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 143 results

Early research (Phase 1)Looking for participantsNCT06096974
What this trial is testing

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Who this might be right for
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd. 60
Early research (Phase 1)Study completedNCT06056024
What this trial is testing

Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Who this might be right for
Solid Tumor, KRAS Mutation
Boehringer Ingelheim 47
Early research (Phase 1)Active Not RecruitingNCT05010694
What this trial is testing

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Who this might be right for
Advanced Solid Tumors Harboring With G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT04956640
What this trial is testing

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Who this might be right for
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more
Eli Lilly and Company 540
Early research (Phase 1)Looking for participantsNCT06720987
What this trial is testing

Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Who this might be right for
KRAS G12C MutationKRAS G12S MutationSolid Tumor Malignancies+1 more
Kumquat Biosciences Inc. 128
Testing effectiveness (Phase 2)Ended earlyNCT01562899
What this trial is testing

MEK162 and AMG 479 in Patients With Selected Solid Tumors

Who this might be right for
Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
Pfizer 77
Early research (Phase 1)Study completedNCT04742556
What this trial is testing

Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Early research (Phase 1)UnknownNCT05202561
What this trial is testing

RNA Tumor Vaccine in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
The First Affiliated Hospital of Bengbu Medical University 10
Early research (Phase 1)Ended earlyNCT05375084
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Who this might be right for
Non Small Cell Lung CancerSolid Tumor
Navire Pharma Inc., a BridgeBio company 21
Early research (Phase 1)Active Not RecruitingNCT04111458
What this trial is testing

Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Who this might be right for
Solid Tumors, KRAS Mutation; SOS1
Boehringer Ingelheim 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT02079740
What this trial is testing

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 96
Early research (Phase 1)Looking for participantsNCT06253520
What this trial is testing

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Who this might be right for
Metastatic Solid CancersColorectal CancerBreast Cancer+4 more
National Cancer Institute (NCI) 210
Testing effectiveness (Phase 2)Looking for participantsNCT07023731
What this trial is testing

Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Who this might be right for
KRAS G12D MutationAdvanced Solid Cancer
Arvinas Inc. 159
Testing effectiveness (Phase 2)Looking for participantsNCT06237413
What this trial is testing

ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Who this might be right for
Solid TumorKRAS Mutation-Related Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 110
Early research (Phase 1)Not Yet RecruitingNCT06594874
What this trial is testing

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd. 350
Testing effectiveness (Phase 2)Ended earlyNCT05071183
What this trial is testing

Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Who this might be right for
KRAS Mutation-Related TumorsMetastatic Solid TumorAdvanced Solid Tumor
Turning Point Therapeutics, Inc. 9
Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Looking for participantsNCT06959615
What this trial is testing

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Who this might be right for
Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd. 334
Early research (Phase 1)Study completedNCT03101839
What this trial is testing

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid Tumours
AstraZeneca 28
Load More Results